GlassScriptPhysician profile
Nathan James Forker
NPI 1285293548
$1,809.31
in general payments reported to CMS, 2019-2025
20 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $538 · 2024: $797 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,809.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $503.39 | 2023-2025 | Farxiga, Lokelma, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.66 | 2023-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $174.80 | 2024 | Lifevest |
| Pfizer INC. | $162.40 | 2023-2024 | |
| Kestra Medical Technology Services, INC. | $160.53 | 2024 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $112.59 | 2023-2024 | |
| Scpharmaceuticals INC. | $101.78 | 2023-2024 | |
| Novo Nordisk INC | $54.14 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Irhythm Technologies, INC. | $48.24 | 2024 | Zio Monitor, Zio Xt Patch |
| Lexicon Pharmaceuticals, INC. | $47.96 | 2023-2024 | Inpefa |
| Amgen INC. | $37.96 | 2025 | Repatha |
| Medtronic, INC. | $33.98 | 2024 | Onyx Frontier |
| Actelion Pharmaceuticals US, INC. | $30.63 | 2023 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals, LTD. | $22.91 | 2023 | Arcalyst |
| Chiesi USA, INC. | $20.85 | 2023 | Kengreal |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $19.34 | 2025 | Onpattro |
| Glaxosmithkline, LLC. | $15.44 | 2025 | Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $14.60 | 2023 | Camzyos |
| Sanofi-Aventis U.S. LLC | $14.19 | 2024 | |
| Merck Sharp & Dohme LLC | $12.92 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Forker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.